Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb 19;9(2):e025469.
doi: 10.1136/bmjopen-2018-025469.

Neuropsychiatric Genetics of African Populations-Psychosis (NeuroGAP-Psychosis): a case-control study protocol and GWAS in Ethiopia, Kenya, South Africa and Uganda

Anne Stevenson #  1   2 , Dickens Akena #  3 , Rocky E Stroud  1   2 , Lukoye Atwoli  4 , Megan M Campbell  5 , Lori B Chibnik  1   2 , Edith Kwobah  6 , Symon M Kariuki  7   8 , Alicia R Martin  2   9 , Victoria de Menil  1   2 , Charles R J C Newton  7   8 , Goodman Sibeko  5 , Dan J Stein  5   10 , Solomon Teferra  11 , Zukiswa Zingela  12 , Karestan C Koenen  1   2
Affiliations

Neuropsychiatric Genetics of African Populations-Psychosis (NeuroGAP-Psychosis): a case-control study protocol and GWAS in Ethiopia, Kenya, South Africa and Uganda

Anne Stevenson et al. BMJ Open. .

Abstract

Introduction: Schizophrenia and bipolar disorder account for a large proportion of the global burden of disease. Despite their enormous impact, little is known about their pathophysiology. Given the high heritability of schizophrenia and bipolar disorder, unbiased genetic studies offer the opportunity to gain insight into their neurobiology. However, advances in understanding the genetic architecture of schizophrenia and bipolar disorder have been based almost exclusively on subjects of Northern European ancestry. The Neuropsychiatric Genetics of African Populations-Psychosis (NeuroGAP-Psychosis) project aims to expand our understanding of the causes of schizophrenia and bipolar disorder through large-scale sample collection and analyses in understudied African populations.

Methods and analysis: NeuroGAP-Psychosis is a case-control study of 34 000 participants recruited across multiple sites within Ethiopia, Kenya, South Africa and Uganda. Participants will include individuals who are at least 18 years old with a clinical diagnosis of schizophrenia or bipolar disorder ('psychosis') or those with no history of psychosis. Research assistants will collect phenotype data and saliva for DNA extraction. Data on mental disorders, history of physical health problems, substance use and history of past traumatic events will be collected from all participants.DNA extraction will take place in-country, with genotyping performed at the Broad Institute. The primary analyses will include identifying major groups of participants with similar ancestry using the computation-efficient programme single nucleotide polymorphisms (SNP) weights. This will be followed by a GWAS within and across ancestry groups.

Ethics and dissemination: All participants will be assessed for capacity to consent using the University of California, San Diego Brief Assessment of Capacity to Consent. Those demonstrating capacity to consent will be required to provide informed consent. Ethical clearances to conduct this study have been obtained from all participating sites. Findings from this study will be disseminated in publications and shared with controlled access public databases, such as the database of Genotypes and Phenotypes, dbGaP.

Keywords: Africa; genetics; mental Health.

PubMed Disclaimer

Conflict of interest statement

Competing interests: DS has received research grants and/or consultancy honoraria from Biocodex, Lundbeck, Servier and Sun.

Figures

Figure 1
Figure 1
Proposed collection sites for Neuropsychiatric Genetics of African Populations-Psychosis.
Figure 2
Figure 2
Phenotyping tools for study participants. ASSIST, Alcohol, Smoking and Substance Involvement Screening Test, V.3.0; CIDI, Composite International Diagnostic Interview screener; K10, Kessler Psychological Distress Scale; LEC-5, Life Events Checklist for Diagnostic and Statistical Manual of Mental Disorders-5; MINI, Mini International Neuropsychiatric Interview, Standard 7.0.2 for Diagnostic and Statistical Manual of Mental Disorders-5. PSQ, Psychosis Screening Questionnaire.
Figure 3
Figure 3
The study process for cases and controls. ASSIST, Alcohol, Smoking and Substance Involvement Screening Test, V.3.0; CIDI, Composite International Diagnostic Interview screener; K10, Kessler Psychological Distress Scale; LEC-5, Life Events Checklist for Diagnostic and Statistical Manual of Mental Disorders-5; MINI, Mini International Neuropsychiatric Interview, Standard 7.0.2 for Diagnostic and Statistical Manual of Mental Disorders-5; PSQ, Psychosis Screening Questionnaire; RA, research assistant; UBACC, University of California, San Diego Brief Assessment of Capacity to Consent.
Figure 4
Figure 4
NeuroGAP-Psychosis training checklist. ASSIST, Alcohol, Smoking and Substance Involvement Screening Test, V.3.0; CIDI, Composite International Diagnostic Interview screener; K10, Kessler Psychological Distress Scale; LEC-5, Life Events Checklist for Diagnostic and Statistical Manual of Mental Disorders-5; MINI, Mini International Neuropsychiatric Interview, Standard 7.0.2 for Diagnostic and Statistical Manual of Mental Disorders-5; NeuroGAP-Psychosis, Neuropsychiatric Genetics of African Populations-Psychosis; PI, Principal Investigator; PSQ, Psychosis Screening Questionnaire; UBACC, University of California, San Diego Brief Assessment of Capacity to Consent.
See this image and copyright information in PMC

References

    1. Whiteford HA, Ferrari AJ, Degenhardt L, et al. . Global Burden of Mental, Neurological, and Substance Use Disorders: An Analysis from the Global Burden of Disease Study 2010 : Patel V, Chisholm D, Dua T, Mental, neurological, and substance use disorders: disease control priorities. 3rd edn Washington (DC): The International Bank for Reconstruction and Development / The World Bank (c) 2016 International Bank for Reconstruction and Development / The World Bank, 2016. - PubMed
    1. Whiteford HA, Degenhardt L, Rehm J, et al. . Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 2013;382:1575–86. 10.1016/S0140-6736(13)61611-6 - DOI - PubMed
    1. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014;511:421–7. 10.1038/nature13595 - DOI - PMC - PubMed
    1. Pardiñas AF, Holmans P, Pocklington AJ, et al. . Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. Nat Genet 2018;50:381–9. 10.1038/s41588-018-0059-2 - DOI - PMC - PubMed
    1. Zeggini E, Ioannidis JP. Meta-analysis in genome-wide association studies. Pharmacogenomics 2009;10:191–201. 10.2217/14622416.10.2.191 - DOI - PMC - PubMed

Publication types